Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label, multicenter post-marketing study of Voncento in von Willebrand disease
2013-003305-25Phase 4Completed
- Sponsor
- CSL Limited
- Start
- May 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of factor viii + von Willebrand factor in von Willebrand disease (VWD), sponsored by CSL Limited. Primary endpoints: Primary hemostatic efficacy and Safety of Voncento. Started May 2015; status: completed.
02
Drugs
factor viii + von Willebrand factor
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2013-003305-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003305-25.